Mekonos Inc.

Mekonos Inc. is a Silicon Valley-based startup with the slogan "Building the future of cell therapies on a chip." Established in 2017, the company operates in the Biotechnology, Robotics, and Semiconductor industries, with its headquarters located in the United States. Mekonos is focused on developing a proprietary cell-engineering platform based on scalable silicon technology, catering to partners engaged in cell & gene therapies and cell line development. The company recently secured a notable $25.00M Series A investment on 09 November 2021, with participation from a diverse group of investors including Novartis, Sands Capital Ventures, Debiopharm Innovation Fund, Elementum Ventures, Fiscus Ventures, Peak 6, Reimagined Ventures, Section 32, and TDK Ventures. This substantial investment signifies a strong vote of confidence from prominent players within the life sciences and venture capital sectors. Mekonos Inc.'s innovative and ambitious approach to cell-engineering technology, coupled with significant support from reputable investors, positions the company as a compelling player in the rapidly evolving field of biotechnology and life sciences.